ArticleInternal medicine (Tokyo, Japan)2026

Ramosetron as a Supportive Agent to Continue Nintedanib in Patients with Interstitial Lung Disease.

Yoshio Satonaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.